Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission.
Wei AH, Döhner H, Pocock C, Montesinos P, Afanasyev B, Dombret H, Ravandi F, Sayar H, Jang JH, Porkka K, Selleslag D, Sandhu I, Turgut M, Giai V, Ofran Y, Kizil Çakar M, Botelho de Sousa A, Rybka J, Frairia C, Borin L, Beltrami G, Čermák J, Ossenkoppele GJ, La Torre I, Skikne B, Kumar K, Dong Q, Beach CL, Roboz GJ; QUAZAR AML-001 Trial Investigators. Wei AH, et al. Among authors: kizil cakar m. N Engl J Med. 2020 Dec 24;383(26):2526-2537. doi: 10.1056/NEJMoa2004444. N Engl J Med. 2020. PMID: 33369355 Clinical Trial.
The effect of gemcitabine, dexamethasone, and cisplatin chemotherapy in relapsed/refractory NHL and HL patients: A single center experience.
Batgi H, Merdin A, Dal MS, Kızıl Çakar M, Yıldız J, Başçı S, Uncu Ulu B, Yiğenoğlu TN, Darçın T, Şahin D, Bakırtaş M, Tetik A, İskender D, Altuntaş F. Batgi H, et al. Among authors: kizil cakar m. J Oncol Pharm Pract. 2020 Dec;26(8):1857-1863. doi: 10.1177/1078155220905654. Epub 2020 Feb 25. J Oncol Pharm Pract. 2020. PMID: 32098553
Gemcitabine, dexamethasone and cisplatin (GDP) is an effective and well-tolerated mobilization regimen for relapsed and refractory lymphoma: a single center experience.
Batgi H, Başcı S, Dal MS, Kızıl Çakar M, Uncu Ulu B, Yiğenoğlu TN, Özcan N, Kılınç A, Merdin A, Yıldız J, Bakırtaş M, Şahin D, Darçın T, İskender D, Baysal NA, Altuntaş F. Batgi H, et al. Among authors: kizil cakar m. Turk J Med Sci. 2021 Apr 30;51(2):685-692. doi: 10.3906/sag-2008-114. Turk J Med Sci. 2021. PMID: 33237657 Free PMC article.
Brentuximab vedotin and bendamustine: an effective salvage therapy for relapsed or refractory Hodgkin lymphoma patients.
Uncu Ulu B, Dal MS, Yönal Hindilerden İ, Akay OM, Mehtap Ö, Büyükkurt N, Hindilerden F, Güneş AK, Yiğenoğlu TN, Başcı S, Kızıl Çakar M, Yanardağ Açık D, Korkmaz S, Ulaş T, Özet G, Ferhanoğlu B, Nalçacı M, Altuntaş F. Uncu Ulu B, et al. Among authors: kizil cakar m. J Chemother. 2022 May;34(3):190-198. doi: 10.1080/1120009X.2021.1976912. Epub 2021 Sep 13. J Chemother. 2022. PMID: 34514960
Molecular evaluation of mutations in acute myeloid leukemia patients from Turkey: A single-center study.
Merdin A, Dal MS, Kizil Çakar M, Bahsi T, Düzkale N, Yildiz J, Bakirtaş M, Başçi S, Darçin T, Şahin D, Tetik A, Uncu Ulu B, İskender D, Yiğenoğlu TN, Altuntaş F. Merdin A, et al. Among authors: kizil cakar m. Medicine (Baltimore). 2021 Oct 15;100(41):e27458. doi: 10.1097/MD.0000000000027458. Medicine (Baltimore). 2021. PMID: 34731121 Free PMC article.
23 results